Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas

Authors: Agda KB Lucio-Eterovic, Maria AA Cortez, Elvis T Valera, Fabio JN Motta, Rosane GP Queiroz, Helio R Machado, Carlos G Carlotti Jr, Luciano Neder, Carlos A Scrideli, Luiz G Tone

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Glioblastoma is the most lethal primary malignant brain tumor. Although considerable progress has been made in the treatment of this aggressive tumor, the clinical outcome for patients remains poor. Histone deacetylases (HDACs) are recognized as promising targets for cancer treatment. In the past several years, HDAC inhibitors (HDACis) have been used as radiosensitizers in glioblastoma treatment. However, no study has demonstrated the status of global HDAC expression in gliomas and its possible correlation to the use of HDACis. The purpose of this study was to evaluate and compare mRNA and protein levels of class I, II and IV of HDACs in low grade and high grade astrocytomas and normal brain tissue and to correlate the findings with the malignancy in astrocytomas.

Methods

Forty-three microdissected patient tumor samples were evaluated. The histopathologic diagnoses were 20 low-grade gliomas (13 grade I and 7 grade II) and 23 high-grade gliomas (5 grade III and 18 glioblastomas). Eleven normal cerebral tissue samples were also analyzed (54 total samples analyzed). mRNA expression of class I, II, and IV HDACs was studied by quantitative real-time polymerase chain reaction and normalized to the housekeeping gene β-glucuronidase. Protein levels were evaluated by western blotting.

Results

We found that mRNA levels of class II and IV HDACs were downregulated in glioblastomas compared to low-grade astrocytomas and normal brain tissue (7 in 8 genes, p < 0.05). The protein levels of class II HDAC9 were also lower in high-grade astrocytomas than in low-grade astrocytomas and normal brain tissue. Additionally, we found that histone H3 (but not histone H4) was more acetylated in glioblastomas than normal brain tissue.

Conclusion

Our study establishes a negative correlation between HDAC gene expression and the glioma grade suggesting that class II and IV HDACs might play an important role in glioma malignancy. Evaluation of histone acetylation levels showed that histone H3 is more acetylated in glioblastomas than normal brain tissue confirming the downregulation of HDAC mRNA in glioblastomas.
Appendix
Available only for authorised users
Literature
1.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007, 114 (2): 97-109. 10.1007/s00401-007-0243-4.CrossRefPubMedPubMedCentral
2.
Lin HY, Chen CS, Lin SP, Weng JR, Chen CS: Targeting histone deacetylase in cancer therapy. Medicinal research reviews. 2006, 26 (4): 397-413. 10.1002/med.20056.CrossRefPubMed
3.
Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Human molecular genetics. 2001, 10 (7): 693-698. 10.1093/hmg/10.7.693.CrossRefPubMed
4.
Gray SG, Ekstrom TJ: The human histone deacetylase family. Experimental cell research. 2001, 262 (2): 75-83. 10.1006/excr.2000.5080.CrossRefPubMed
5.
Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell research. 2007, 17 (3): 195-211.PubMed
6.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical journal. 2003, 370 (Pt 3): 737-749. 10.1042/BJ20021321.CrossRefPubMedPubMedCentral
7.
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D: Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & development. 1999, 13 (15): 1924-1935. 10.1101/gad.13.15.1924.CrossRef
8.
Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of biological chemistry. 2006, 281 (19): 13548-13558. 10.1074/jbc.M510023200.CrossRefPubMed
9.
Grozinger CM, Hassig CA, Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proceedings of the National Academy of Sciences of the United States of America. 1999, 96 (9): 4868-4873. 10.1073/pnas.96.9.4868.CrossRefPubMedPubMedCentral
10.
Verdin E, Dequiedt F, Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19 (5): 286-293. 10.1016/S0168-9525(03)00073-8.CrossRefPubMed
11.
Kao HY, Downes M, Ordentlich P, Evans RM: Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes & development. 2000, 14 (1): 55-66.
12.
Verdel A, Khochbin S: Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. The Journal of biological chemistry. 1999, 274 (4): 2440-2445. 10.1074/jbc.274.4.2440.CrossRefPubMed
13.
Lemercier C, Verdel A, Galloo B, Curtet S, Brocard MP, Khochbin S: mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity. The Journal of biological chemistry. 2000, 275 (20): 15594-15599. 10.1074/jbc.M908437199.CrossRefPubMed
14.
Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T: HDAC4 deacetylase associates with and represses the MEF2 transcription factor. The EMBO journal. 1999, 18 (18): 5099-5107. 10.1093/emboj/18.18.5099.CrossRefPubMedPubMedCentral
15.
Wang AH, Bertos NR, Vezmar M, Pelletier N, Crosato M, Heng HH, Th'ng J, Han J, Yang XJ: HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol. 1999, 19 (11): 7816-7827.CrossRefPubMedPubMedCentral
16.
Blander G, Guarente L: The Sir2 family of protein deacetylases. Annual review of biochemistry. 2004, 73: 417-435. 10.1146/annurev.biochem.73.011303.073651.CrossRefPubMed
17.
Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000, 403 (6771): 795-800. 10.1038/35001622.CrossRefPubMed
18.
Marmorstein R: Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochemical Society transactions. 2004, 32 (Pt 6): 904-909.CrossRefPubMed
19.
Gao L, Cueto MA, Asselbergs F, Atadja P: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. The Journal of biological chemistry. 2002, 277 (28): 25748-25755. 10.1074/jbc.M111871200.CrossRefPubMed
20.
Lopez CA, Feng FY, Herman JM, Nyati MK, Lawrence TS, Ljungman M: Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. International journal of radiation oncology, biology, physics. 2007, 69 (1): 214-220.CrossRefPubMed
21.
Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. International journal of cancer. 2005, 114 (3): 380-386. 10.1002/ijc.20774.CrossRefPubMed
22.
Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA: In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology. 2007, 9 (2): 82-88. 10.1215/15228517-2006-032.CrossRefPubMedPubMedCentral
23.
Kim JH, Shin JH, Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. International journal of radiation oncology, biology, physics. 2004, 59 (4): 1174-1180. 10.1016/j.ijrobp.2004.03.001.CrossRefPubMed
24.
Sawa H, Murakami H, Kumagai M, Nakasato M, Yamauchi S, Matsuyama N, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H: Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta neuropathologica. 2004, 107 (6): 523-531. 10.1007/s00401-004-0841-3.CrossRefPubMed
25.
Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, Carroll RS: Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of neuro-oncology. 2007, 83 (3): 267-275. 10.1007/s11060-007-9337-z.CrossRefPubMed
26.
Wetzel M, Premkumar DR, Arnold B, Pollack IF: Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis. Journal of neurosurgery. 2005, 103 (6 Suppl): 549-556.PubMed
27.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227 (5259): 680-685. 10.1038/227680a0.CrossRefPubMed
28.
Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell death and differentiation. 2005, 12 (4): 395-404. 10.1038/sj.cdd.4401567.CrossRefPubMed
29.
Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY: Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res. 2001, 92 (12): 1300-1304.CrossRefPubMed
30.
Liby P, Kostrouchova M, Pohludka M, Yilma P, Hrabal P, Sikora J, Brozova E, Kostrouchova M, Rall JE, Kostrouch Z: Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours. Folia biologica. 2006, 52 (1-2): 21-33.PubMed
31.
Ozdag H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C: Differential expression of selected histone modifier genes in human solid cancers. BMC genomics. 2006, 7: 90-10.1186/1471-2164-7-90.CrossRefPubMedPubMedCentral
32.
Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International journal of cancer. 2004, 112 (1): 26-32. 10.1002/ijc.20395.CrossRefPubMed
33.
Goussia AC, Agnantis NJ, Rao JS, Kyritsis AP: Cytogenetic and molecular abnormalities in astrocytic gliomas (Review). Oncology reports. 2000, 7 (2): 401-412.PubMed
34.
Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, Aldape K, Sawaya R, Bruner JM, Fuller GN, Zhang W: Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics. 2006, 6 (10): 2964-2971. 10.1002/pmic.200500555.CrossRefPubMed
35.
Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology. 1999, 1 (1): 44-51. 10.1215/15228517-1-1-44.PubMedPubMedCentral
36.
Michotte A, Neyns B, Chaskis C, Sadones J, In 't Veld P: Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta neurologica Belgica. 2004, 104 (4): 148-153.PubMed
37.
Ng HK, Lam PY: The molecular genetics of central nervous system tumors. Pathology. 1998, 30 (2): 196-202. 10.1080/00313029800169236.CrossRefPubMed
38.
Kolle D, Brosch G, Lechner T, Pipal A, Helliger W, Taplick J, Loidl P: Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry. 1999, 38 (21): 6769-6773. 10.1021/bi982702v.CrossRefPubMed
39.
Riester D, Hildmann C, Grunewald S, Beckers T, Schwienhorst A: Factors affecting the substrate specificity of histone deacetylases. Biochemical and biophysical research communications. 2007, 357 (2): 439-445. 10.1016/j.bbrc.2007.03.158.CrossRefPubMed
40.
Wegener D, Hildmann C, Riester D, Schwienhorst A: Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Analytical biochemistry. 2003, 321 (2): 202-208. 10.1016/S0003-2697(03)00426-3.CrossRefPubMed
41.
Wiren M, Silverstein RA, Sinha I, Walfridsson J, Lee HM, Laurenson P, Pillus L, Robyr D, Grunstein M, Ekwall K: Genomewide analysis of nucleosome density histone acetylation and HDAC function in fission yeast. The EMBO journal. 2005, 24 (16): 2906-2918. 10.1038/sj.emboj.7600758.CrossRefPubMedPubMedCentral
42.
Brinkmann H, Dahler AL, Popa C, Serewko MM, Parsons PG, Gabrielli BG, Burgess AJ, Saunders NA: Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. The Journal of biological chemistry. 2001, 276 (25): 22491-22499. 10.1074/jbc.M100206200.CrossRefPubMed
43.
Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer cell. 2003, 4 (1): 13-18. 10.1016/S1535-6108(03)00165-X.CrossRefPubMed
44.
Acharya MR, Sparreboom A, Venitz J, Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular pharmacology. 2005, 68 (4): 917-932. 10.1124/mol.105.014167.CrossRefPubMed
45.
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annual review of pharmacology and toxicology. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.CrossRefPubMed
Metadata
Title
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas
Authors
Agda KB Lucio-Eterovic
Maria AA Cortez
Elvis T Valera
Fabio JN Motta
Rosane GP Queiroz
Helio R Machado
Carlos G Carlotti Jr
Luciano Neder
Carlos A Scrideli
Luiz G Tone
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-243

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Self evaluation of communication experiences after laryngeal cancer – A longitudinal questionnaire study in patients with laryngeal cancer

Research article

Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0

Research article

Bioelectrical impedance phase angle as a prognostic indicator in breast cancer

Study protocol

ProsCan for Men: Randomised controlled trial of a decision support intervention for men with localised prostate cancer

Research article

Expression of TRPC6 channels in human epithelial breast cancer cells

Research article

Association between H-RAST81C genetic polymorphism and gastrointestinal cancer risk: A population based case-control study in China
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits